Humanigen Inc (HGEN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Humanigen Inc (HGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8001
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Humanigen Inc (Humanigen), formerly KaloBios Pharmaceuticals Inc is a biopharmaceutical company that develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company provides Ifabotuzumab(anti-EphA3) and Lenzilumab(anti-GM-CSF) recombinant monoclonal antibodies, used for the treatment of solid tumors and their micro environment; and certain hematologic malignancies such as chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. It has developed the recombinant monoclonal antibodies using its proprietary drug discovery technology called Humaneered. Humanigen also provides data on on pharmacokinetics and pharmacodynamics including correlative biomarkers and mutational analysis for conducting studies in and juvenile myelomonocytic leukemia. Humanigen is headquartered in Brisbane, California, the US.

Humanigen Inc (HGEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Humanigen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Humanigen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Humanigen Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
KaloBios Pharma Acquires Benznidazole Program from Savant Neglected Diseases 11
Venture Financing 12
KaloBios Pharma Raises USD12.2 Million in Venture Financing 12
Kalobios Pharma Raises Additional US$3 Million In Series E Financing 13
Partnerships 14
Humanigen Enters into Research Agreement with MD Anderson Cancer Center 14
Equity Offering 15
Humanigen Plans to Raise up to USD15 Million in Private Placement of Shares 15
KaloBios Pharma Plans to Raise Funds through Public Offering of Shares 16
KaloBios Pharma to Raise Funds through Private Placement of Shares, upon Exercise of Warrant 17
KaloBios Pharma Raises USD8.8 Million in Private Placement of Shares 18
KaloBios Pharma Completes Public Offering Of Shares For US$34.5 Million 19
KaloBios Pharma Completes IPO For US$70 Million 21
Acquisition 24
Martin Shkreli Led Consortium Acquires 70% Stake in KaloBios Pharma 24
Humanigen Inc – Key Competitors 25
Humanigen Inc – Key Employees 26
Humanigen Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Corporate Communications 28
Mar 12, 2018: Humanigen Appoints Robert Savage to Board of Directors 28
Feb 07, 2018: Humanigen Names Rainer Boehm As Board Director 29
Aug 28, 2017: Humanigen Appoints Chief Financial Officer 30
Product News 31
04/06/2017: Benznidazole on Track in Progress to IND and NDA Submissions 31
Product Approvals 32
Jul 11, 2017: KaloBios Receives Orphan Drug Designation for Benznidazole in the Treatment of Chagas Disease 32
Jun 27, 2017: Benznidazole IND for Chagas Disease Receives Clearance by FDA 33
May 30, 2017: KaloBios Submits IND Application for Benznidazole to FDA 34
Jan 05, 2017: KaloBios Announces Positive Guidance from FDA for Benznidazole 35
Clinical Trials 36
Aug 08, 2017: Humanigen Announces Completion of Benznidazole Bioavailability Study 36
Other Significant Developments 37
Aug 07, 2017: Humanigen is Effective Today 37
Jul 27, 2017: KaloBios To Change Company Name To Humanigen 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
Humanigen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Humanigen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Humanigen Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Humanigen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
KaloBios Pharma Acquires Benznidazole Program from Savant Neglected Diseases 11
KaloBios Pharma Raises USD12.2 Million in Venture Financing 12
Kalobios Pharma Raises Additional US$3 Million In Series E Financing 13
Humanigen Enters into Research Agreement with MD Anderson Cancer Center 14
Humanigen Plans to Raise up to USD15 Million in Private Placement of Shares 15
KaloBios Pharma Plans to Raise Funds through Public Offering of Shares 16
KaloBios Pharma to Raise Funds through Private Placement of Shares, upon Exercise of Warrant 17
KaloBios Pharma Raises USD8.8 Million in Private Placement of Shares 18
KaloBios Pharma Completes Public Offering Of Shares For US$34.5 Million 19
KaloBios Pharma Completes IPO For US$70 Million 21
Martin Shkreli Led Consortium Acquires 70% Stake in KaloBios Pharma 24
Humanigen Inc, Key Competitors 25
Humanigen Inc, Key Employees 26
Humanigen Inc, Subsidiaries 27

List of Figures
Humanigen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Humanigen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Humanigen Inc (HGEN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Rheonix Inc:医療機器:M&Aディール及び事業提携情報
    Summary Rheonix Inc (Rheonix) is a medical equipment company that develops molecular diagnostic products. The company offers automated and integrated molecular testing device. It develops Rheonix CARD cartridge technology which penetrates molecular testing markets from diagnostics labs to applied ma …
  • Total Energy Services Inc. (TOT):企業の財務・戦略的SWOT分析
    Total Energy Services Inc. (TOT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Alexion Pharmaceuticals Inc (ALXN):企業の財務・戦略的SWOT分析
    Alexion Pharmaceuticals Inc (ALXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Subex Ltd (SUBEX):企業の財務・戦略的SWOT分析
    Subex Ltd (SUBEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Tizona Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tizona Therapeutics Inc (Tizona Therapeutics) is an immunology company which develops treatments for cancer and autoimmune disorders. Its lead product candidate anti-CD39 antibody inhibits the breakdown of excessive ATP released from dying tumor cells to immune suppressive adenosine leading …
  • The Hospital for Sick Children-製薬・医療分野:企業M&A・提携分析
    Summary The Hospital for Sick Children (SickKids) is a healthcare service provider that offers children care services. The hospital offers programs and services including resources, tele-medicine, accommodations, child life, creative arts therapy, child and family-centered care; health records inqui …
  • Pulmagen Therapeutics LLP:製薬・医療:M&Aディール及び事業提携情報
    Summary Pulmagen Therapeutics LLP (Pulmagen) formerly Argenta Discovery Ltd, is a development stage pharmaceutical company, which develops oral and inhaled medicines for chronic respiratory diseases. The company’s product pipeline includes oral CRTh2 antagonists, inhaled bronchodilators, inhaled per …
  • Therabron Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Therabron Therapeutics Inc (Therabron), formerly Clarassance Inc is a clinical-stage biopharmaceutical company that develops drugs based on secretoglobin family of proteins. The company’s lead biopharmaceutical candidate includes CG100, CG201, CG367, CG459 and CG1011. Its CC10 protein candid …
  • Eregli Demir ve Celik Fabrikalari TAS:企業の戦略・SWOT・財務情報
    Eregli Demir ve Celik Fabrikalari TAS - Strategy, SWOT and Corporate Finance Report Summary Eregli Demir ve Celik Fabrikalari TAS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Italcementi S.p.A:企業の戦略的SWOT分析
    Italcementi S.p.A - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Belvedere International Inc.:企業の戦略・SWOT・財務情報
    Belvedere International Inc. - Strategy, SWOT and Corporate Finance Report Summary Belvedere International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Enel Americas S A (ENELAM):企業の財務・戦略的SWOT分析
    Enel Americas S A (ENELAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Greene King PLC:企業の戦略・SWOT・財務情報
    Greene King PLC - Strategy, SWOT and Corporate Finance Report Summary Greene King PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Presidio Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Presidio Pharmaceuticals Inc (Presidio) is a clinical-stage pharmaceutical company that discovers and develops small-molecule antiviral therapeutics. The company’s products include HCV NS5A, NS5B proteins, lead pan-genotypic HCV NS5A inhibitor, ravidasvir hydrochloride, protease inhibitor, f …
  • The Quaker Oats Company:企業の戦略・SWOT・財務情報
    The Quaker Oats Company - Strategy, SWOT and Corporate Finance Report Summary The Quaker Oats Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Ernst & Young Global Ltd:企業の戦略・SWOT・財務分析
    Ernst & Young Global Ltd - Strategy, SWOT and Corporate Finance Report Summary Ernst & Young Global Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • SMBC Trust Bank Private Banking:企業の戦略・SWOT・財務情報
    SMBC Trust Bank Private Banking - Strategy, SWOT and Corporate Finance Report Summary SMBC Trust Bank Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Duke Realty Corporation:企業の戦略・SWOT・財務情報
    Duke Realty Corporation - Strategy, SWOT and Corporate Finance Report Summary Duke Realty Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Bio-Reference Laboratories Inc:企業の戦略的SWOT分析
    Bio-Reference Laboratories Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • BioLineRx Ltd (BLRX):企業の財務・戦略的SWOT分析
    BioLineRx Ltd (BLRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆